Latest News
European Commission approves Insmed's BRINSUPRI for the treatment of non-cystic fibrosis bronchiectasis
18 November 2025 - US-based biopharmaceutical company Insmed Incorporated (Nasdaq: INSM) said on Tuesday that the European Commission has approved BRINSUPRI (brensocatib 25mg tablets) for patients with non-cystic fibrosis bronchiectasis aged 12 and o...
Genentech reports first oral SERD to improve invasive disease-free survival in early breast cancer
18 November 2025 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), announced on Tuesday that its Phase III lidERA trial of giredestrant met its primary endpoint in early-stage ER-positive, HER2-negative bre...
European Commission approves Celltrion's Remsima IV liquid formulation
18 November 2025 - South Korea-based biopharmaceutical company Celltrion Inc (KRX:068270) announced on Tuesday that the European Commission has granted marketing authorisation for Remsima IV liquid formulation, the world's first liquid version o...
TIRmed Pharma partners with Bachem to advance production of atopic dermatitis therapy
18 November 2025 - Sweden-based biotechnology company TIRmed Pharma, which develops immunomodulatory therapies for autoimmune skin diseases, announced on Tuesday that it has entered a manufacturing collaboration with Swiss biotechnology company Bache...
Biotheryx completes enrolment in ongoing Phase 1a trial of BTX-9341 for HR+/HER2- breast cancer
18 November 2025 - Biotheryx Inc, a biopharmaceutical company focused on the discovery and development of first-in-class protein degraders for cancer and inflammatory diseases, on Monday announced the completion of enrolment in the ongoing Phase 1a c...